https://www.missourihealthdigest.com/article/910696959-avalo-therapeutics-announces-pricing-of-375-million-public-offering Missouri Health Digest en PressRelease 2026-05-06T03:33:54+00:00 Avalo Therapeutics Announces Pricing of $375 Million Public Offering https://ml.globenewswire.com/media/950a0fc1-6e06-40b5-9adc-6d3d9f2d5e78/small/avalo-final-black-01-jpg.jpg https://www.missourihealthdigest.com/article/910696876-lbl-047-prioritized-for-clinical-development-in-sj-gren-s-disease-systemic-lupus-erythematosus-and-dermatomyositis Missouri Health Digest en PressRelease 2026-05-06T02:57:21+00:00 LBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and Dermatomyositis https://ml.globenewswire.com/media/YjZkMjQxNjctYjA3Ni00YmZkLThkMGMtZDhmZTMzNGI3ZTMxLTEzMDgzODktMjAyNi0wNS0wNi1lbg==/tiny/LEADS-BIOLABS-CO-LTD-.png https://www.missourihealthdigest.com/article/910686158-writeupp-introduces-embedded-ai-medical-scribe-with-soap-dap-and-birp-note-generation-at-ca-40-per-user Missouri Health Digest en PressRelease 2026-05-06T02:45:54+00:00 WriteUpp Introduces Embedded AI Medical Scribe With SOAP, DAP and BIRP Note Generation at CA$40 Per User https://ml.globenewswire.com/media/a75e2abd-2872-4427-9104-2e700e6a8340/medium/writeupp-introduces-embedded-ai-medical-scribe-with-soap-dap.png https://www.missourihealthdigest.com/article/910661966-rapid-nutrition-enhances-investor-access-with-agentic-ai-driven-on-demand-communication-platform Missouri Health Digest en PressRelease 2026-05-06T00:27:06+00:00 Rapid Nutrition Enhances Investor Access with Agentic AI driven On-Demand Communication Platform https://ml-eu.globenewswire.com/media/f5152816-94d7-4584-a49f-05ae66a44bf0/small/rapid-jpg.jpg https://www.missourihealthdigest.com/article/910636745-isothrive-reports-highly-statistically-significant-phase-2-data-for-mhs-1031-in-nerd-patients-at-ddw-2026 Missouri Health Digest en PressRelease 2026-05-05T22:16:13+00:00 ISOThrive Reports Highly Statistically Significant Phase 2 Data for MHS-1031 in NERD Patients at DDW 2026 https://ml.globenewswire.com/media/bbf9967c-a7fb-4fa6-b7e7-3cab0c0479b9/medium/cover-image.jpg https://www.missourihealthdigest.com/article/910624511-biomea-fusion-announces-poster-presentations-of-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions Missouri Health Digest en PressRelease 2026-05-05T21:50:41+00:00 Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions https://ml.globenewswire.com/media/d2f051eb-da8d-4233-9093-8ff1579d035f/small/biomea-fusion-logo-rgb-rev2-email-png.png https://www.missourihealthdigest.com/article/910624458-mineralys-therapeutics-reports-inducement-awards-under-nasdaq-listing-rule-5635-c-4 Missouri Health Digest en PressRelease 2026-05-05T21:34:32+00:00 Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/2f3e6873-8e64-406e-832e-7df0f6d79a56/small/mineralys-therapeutics-logo-jpg.jpg https://www.missourihealthdigest.com/article/910624423-epik-biosciences-launches-to-pioneer-ketamine-powered-psychedelic-therapies-to-transform-treatment-of-mental-health-pain-and-addiction Missouri Health Digest en PressRelease 2026-05-05T21:20:00+00:00 EPIK Biosciences Launches to Pioneer Ketamine-Powered Psychedelic Therapies to Transform Treatment of Mental Health, Pain, and Addiction https://ml.globenewswire.com/media/3ffb3db0-76c3-46ee-84b6-368a18fbeefc/small/epik-png.png https://www.missourihealthdigest.com/article/910612410-aura-biosciences-announces-closing-of-299-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares Missouri Health Digest en PressRelease 2026-05-05T21:15:00+00:00 Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares https://ml.globenewswire.com/media/92103c30-8e5a-4502-9ec4-0f3b3bd9bb83/small/aura-biosciences-1c-orange-large-jpg.jpg https://www.missourihealthdigest.com/article/910611978-steris-announces-dividend-of-0-63-per-share Missouri Health Digest en PressRelease 2026-05-05T20:30:00+00:00 STERIS Announces Dividend of $0.63 per share https://ml.globenewswire.com/media/2c1a9c6d-bc94-4d3f-a47f-0ac0d209f8b6/small/sterishoriz-no-r-rgb-jpg-jpg.jpg https://www.missourihealthdigest.com/article/910612071-theriva-biologics-reports-first-quarter-2026-operational-highlights-and-financial-results Missouri Health Digest en PressRelease 2026-05-05T20:30:00+00:00 Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results https://ml.globenewswire.com/media/ed41908b-8799-4f56-bc3c-acff4f4872eb/small/tovx-logo-jpg.jpg https://www.missourihealthdigest.com/article/910612085-fda-expands-market-access-authorizes-new-ends-products Missouri Health Digest en PressRelease 2026-05-05T20:27:48+00:00 FDA Expands Market Access, Authorizes New ENDS Products https://ml.globenewswire.com/media/YjBiNDNiOTUtOGFkYi00NDg0LTlhYmMtYzJjNWJlNjIxNmY2LTUwMDE1NDE1NC0yMDI2LTA1LTA1LWVu/tiny/FDA.png https://www.missourihealthdigest.com/article/910612052-pacira-biosciences-mails-letter-to-stockholders Missouri Health Digest en PressRelease 2026-05-05T20:20:00+00:00 Pacira BioSciences Mails Letter to Stockholders https://ml.globenewswire.com/media/3e502c92-e576-46b6-b602-a177ab0f5044/small/pacira-biosciences-tm-logo-rgb-v2025-300dpi-adj-png.png https://www.missourihealthdigest.com/article/910599747-longeveron-to-report-2026-first-quarter-financial-results-and-host-conference-call-on-may-13-2026 Missouri Health Digest en PressRelease 2026-05-05T20:15:00+00:00 Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026 https://ml.globenewswire.com/media/a6d6e61c-2a7d-4b22-954b-04b9841fbc38/small/longeveron-logo-jpg.jpg https://www.missourihealthdigest.com/article/910599971-sienna-reports-first-quarter-2026-financial-results-and-continues-platform-expansion Missouri Health Digest en PressRelease 2026-05-05T20:15:00+00:00 Sienna Reports First Quarter 2026 Financial Results and Continues Platform Expansion https://ml.globenewswire.com/media/ac969f39-0111-4903-8faa-0cdee524eb4e/small/sienna-logo-rgb-jpg.jpg https://www.missourihealthdigest.com/article/910600002-cytokinetics-announces-proposed-public-offering-of-common-stock Missouri Health Digest en PressRelease 2026-05-05T20:15:00+00:00 Cytokinetics Announces Proposed Public Offering of Common Stock https://ml.globenewswire.com/media/52e2be9f-e9e3-43af-a747-123fdcac4253/small/cytokinetics-png.png https://www.missourihealthdigest.com/article/910599138-onkure-therapeutics-reports-first-quarter-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 OnKure Therapeutics Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/b01f7b95-9b60-4b2b-8515-fe0cae183fff/small/onkure-logo-jpg.jpg https://www.missourihealthdigest.com/article/910599159-sana-biotechnology-to-present-at-the-bofa-securities-2026-healthcare-conference Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference https://ml.globenewswire.com/media/2e5b81be-ddf0-4a60-85f1-3f17c242e8c2/small/sana-biotechnology-jpg.jpg https://www.missourihealthdigest.com/article/910599164-spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026 Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 https://ml.globenewswire.com/media/aad6f25c-1793-4870-a611-84ea3f25fed3/small/spero-logo-jpg.jpg https://www.missourihealthdigest.com/article/910599178-korro-to-participate-in-upcoming-investor-conferences Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Korro to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/d49fc3c4-5cf6-4b89-8434-2eadfff25c26/small/korro-logo-rgb-jpg.jpg https://www.missourihealthdigest.com/article/910599236-alamar-biosciences-to-participate-in-bofa-securities-2026-healthcare-conference Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference https://ml.globenewswire.com/media/9394cf1d-76c7-4cf9-8ed3-cafcc57c9a84/small/alamardroplogo-4c-png.png https://www.missourihealthdigest.com/article/910599247-trevi-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates https://ml.globenewswire.com/media/b97e9d57-6e8e-4570-87da-ea38c273f7c8/small/trevi-logo-jpg.jpg https://www.missourihealthdigest.com/article/910599249-adaptive-biotechnologies-reports-first-quarter-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Adaptive Biotechnologies Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/6c319974-0bac-45f1-83d9-ae9987dfdf44/small/adpt-new-logo-jpg.jpg https://www.missourihealthdigest.com/article/910599295-cytokinetics-reports-first-quarter-2026-financial-results-and-provides-business-update Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/52e2be9f-e9e3-43af-a747-123fdcac4253/small/cytokinetics-png.png https://www.missourihealthdigest.com/article/910599357-myriad-genetics-reports-first-quarter-2026-financial-results-reiterates-2026-financial-guidance-reflecting-ongoing-progress-in-the-cancer-care Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business https://ml.globenewswire.com/media/5cb679cf-5a10-4b95-8cf7-fd1d0b56721a/small/myriad-s-stacked-png.png https://www.missourihealthdigest.com/article/910599397-iridex-to-report-first-quarter-2026-financial-results-on-may-19-2026 Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Iridex to Report First Quarter 2026 Financial Results on May 19, 2026 https://ml.globenewswire.com/media/2bb80159-a920-428b-aa69-c2f32e3038c9/small/iridex-corporate-logo-horizontal-rgb-m02-jpg.jpg https://www.missourihealthdigest.com/article/910599618-amwell-announces-results-for-first-quarter-2026 Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Amwell® Announces Results for First Quarter 2026 https://ml.globenewswire.com/media/ff1989f5-0a6a-4e00-99dc-cb29a818aca5/small/amwell-logo-blue-2023-v02-rgb-2-png.png https://www.missourihealthdigest.com/article/910599661-avalo-therapeutics-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants https://ml.globenewswire.com/media/950a0fc1-6e06-40b5-9adc-6d3d9f2d5e78/small/avalo-final-black-01-jpg.jpg https://www.missourihealthdigest.com/article/910599743-innovage-announces-financial-results-for-the-fiscal-third-quarter-ended-march-31-2026 Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 InnovAge Announces Financial Results for the Fiscal Third Quarter Ended March 31, 2026 https://ml.globenewswire.com/media/a1b976fe-053f-43be-b43c-532393a7f314/small/inn-logotag-rgb-jpg.jpg https://www.missourihealthdigest.com/article/910599766-standard-biotools-reports-first-quarter-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Standard BioTools Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/122934c3-b763-4386-89d1-3047d0704c17/small/sbt-new-august-2022-logo.png https://www.missourihealthdigest.com/article/910599869-relay-therapeutics-reports-first-quarter-2026-financial-results-and-corporate-updates Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates https://ml.globenewswire.com/media/079b6db5-ce81-4a81-9cde-d97f86c569ae/small/logo-banner-small-png.png https://www.missourihealthdigest.com/article/910600015-supernus-announces-first-quarter-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Supernus Announces First Quarter 2026 Financial Results https://ml.globenewswire.com/media/1fc58442-511b-40c2-a8c0-f1e78b8437b4/small/supernus-pharmaceuticals-inc.jpg https://www.missourihealthdigest.com/article/910600051-lemaitre-q1-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 LeMaitre Q1 2026 Financial Results https://ml.globenewswire.com/media/8b8755b7-6f04-4650-9c94-0a2d0654fd49/small/lemaitre-2color-rgb-jpg.jpg https://www.missourihealthdigest.com/article/910600067-verrica-pharmaceuticals-announces-upcoming-presentation-of-phase-2-data-highlighting-the-potential-abscopal-effects-of-vp-315-in-the-treatment-of Missouri Health Digest en PressRelease 2026-05-05T20:05:00+00:00 Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting  https://ml.globenewswire.com/media/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b/small/verrica-logo-jpg.jpg https://www.missourihealthdigest.com/article/910599241-carlsmed-reports-first-quarter-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Carlsmed® Reports First Quarter 2026 Financial Results  https://ml.globenewswire.com/media/ee16eff2-e0d6-40ca-95c5-4dd84bb4cc5f/small/carlsmed-png.png https://www.missourihealthdigest.com/article/910599255-dianthus-therapeutics-highlights-recent-business-achievements-and-reports-q1-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results https://ml.globenewswire.com/media/c9002285-2240-4dab-aced-77296f86a3fa/small/dianthus-logo-primary-full-color-cmyk-png.png https://www.missourihealthdigest.com/article/910599363-monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/20ed9999-454a-4e2a-aabc-217270a87d2d/small/mrtx-logo-primaryblue-4cp-jpg.jpg https://www.missourihealthdigest.com/article/910599377-avalyn-to-present-patient-centered-research-on-ap01-delivery-and-supportive-care-experiences-at-american-thoracic-society-2026-international Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference https://ml.globenewswire.com/media/84d7bff4-ce17-433b-8c71-aa20c30f9f43/small/avalyn-logo-final-png.png https://www.missourihealthdigest.com/article/910599422-praxis-precision-medicines-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/bff1e728-30ed-46c6-81e1-8bbc795929c0/small/01-primarylogo-color-bluex-100-jpg.jpg https://www.missourihealthdigest.com/article/910599496-ligand-to-participate-in-may-investor-conferences Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Ligand to Participate in May Investor Conferences https://ml.globenewswire.com/media/1fe91aa2-494e-4b30-89e8-cad771bbaabf/small/new-ligand-logo-png.png https://www.missourihealthdigest.com/article/910599599-ultragenyx-reports-first-quarter-2026-financial-results-and-corporate-update Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update https://ml.globenewswire.com/media/121a9bda-7a64-41f8-85e8-1693a2dfa977/small/ultragenyx-cmyk-png.png https://www.missourihealthdigest.com/article/910599621-dentsply-sirona-reports-first-quarter-2026-results Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Dentsply Sirona Reports First Quarter 2026 Results https://ml.globenewswire.com/media/91e36dfa-44e3-4905-a186-3a988bd67ab8/small/dentsply-sirona-grey-80-black-rgb-jpg.JPG https://www.missourihealthdigest.com/article/910599629-avalo-therapeutics-achieves-positive-topline-results-in-phase-2-lotus-trial-of-abdakibart-avtx-009-in-moderate-to-severe-hidradenitis-suppurativa Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa https://ml.globenewswire.com/media/950a0fc1-6e06-40b5-9adc-6d3d9f2d5e78/small/avalo-final-black-01-jpg.jpg https://www.missourihealthdigest.com/article/910599881-hyperion-defi-announces-proposed-public-offering-of-common-stock-and-pre-funded-warrants Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 Hyperion DeFi Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants https://ml.globenewswire.com/media/2b21f207-e46f-4ad9-a6be-573e0bdc6c4c/small/hyperion-defi-single-logo-jpg.jpg https://www.missourihealthdigest.com/article/910599936-healthequity-announces-first-quarter-earnings-release-date-and-investor-conference-schedule Missouri Health Digest en PressRelease 2026-05-05T20:01:00+00:00 HealthEquity Announces First Quarter Earnings Release Date and Investor Conference Schedule https://ml.globenewswire.com/media/30a1510d-03b1-4356-b38d-e9f75f1ec797/small/healthequitylogo-purple-2020-jpg.jpg https://www.missourihealthdigest.com/article/910599226-acumen-pharmaceuticals-to-report-first-quarter-financial-results-on-may-12-2026 Missouri Health Digest en PressRelease 2026-05-05T20:00:00+00:00 Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026 https://ml.globenewswire.com/media/53dd23f0-4b5b-4b6b-9dfa-22b5db4c922b/small/picture1-png.png https://www.missourihealthdigest.com/article/910599338-inmune-bio-and-anthony-nolan-announce-strategic-expansion-of-cordstrom-msc-platform-collaboration-to-target-rdeb-oncology-and-inflammatory-diseases Missouri Health Digest en PressRelease 2026-05-05T20:00:00+00:00 INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases https://ml.globenewswire.com/media/64035ec0-9fc2-414d-a693-27f1b1e90a31/small/logo-png.png https://www.missourihealthdigest.com/article/910587066-context-by-fulcra-dynamics-launches-updated-version-2-4-7-now-with-the-capacity-for-groups Missouri Health Digest en PressRelease 2026-05-05T19:22:00+00:00 Context, by Fulcra Dynamics, Launches Updated Version 2.4.7 - Now With the Capacity for Groups https://pressranger.s3.us-west-1.amazonaws.com/3254028/active_tab.png https://www.missourihealthdigest.com/article/910587060-neuvasq-presents-data-showcasing-promising-novel-multispecific-gpr124-targeting-antibodies-for-blood-retina-barrier-restoration-at-arvo-2026 Missouri Health Digest en PressRelease 2026-05-05T19:15:00+00:00 Neuvasq Presents Data Showcasing Promising Novel Multispecific Gpr124-Targeting Antibodies for Blood Retina Barrier Restoration at ARVO 2026 https://ml.globenewswire.com/media/758fbb1f-ac3c-4f37-ba02-64c0f59beff0/small/neuvasq-logo-png-png.png https://www.missourihealthdigest.com/article/910576181-sk-pharmteco-obtient-la-validation-de-la-sbti-pour-ses-objectifs-scientifiques-de-neutralit-carbone-horizon-2040 Missouri Health Digest en PressRelease 2026-05-05T18:31:06+00:00 SK pharmteco obtient la validation de la SBTi pour ses objectifs scientifiques de neutralité carbone à horizon 2040 https://ml.globenewswire.com/media/038236c2-8cb0-4ff3-8b7e-cbb02b768b37/small/sk-pharmteco-3-png.png https://www.missourihealthdigest.com/article/910576183-sk-pharmteco-erh-lt-sbti-validierung-f-r-wissenschaftsbasierte-netto-null-ziele-bis-2040 Missouri Health Digest en PressRelease 2026-05-05T18:31:06+00:00 SK pharmteco erhält SBTi-Validierung für wissenschaftsbasierte Netto-Null-Ziele bis 2040 https://ml.globenewswire.com/media/038236c2-8cb0-4ff3-8b7e-cbb02b768b37/small/sk-pharmteco-3-png.png https://www.missourihealthdigest.com/article/910576185-sk-pharmteco-2040-sbti Missouri Health Digest en PressRelease 2026-05-05T18:31:06+00:00 SK pharmteco, 2040년 넷제로 과학 기반 목표에 대한 글로벌 기후변화 대응 이니셔티브 (SBTi) 검증 획득 https://ml.globenewswire.com/media/038236c2-8cb0-4ff3-8b7e-cbb02b768b37/small/sk-pharmteco-3-png.png https://www.missourihealthdigest.com/article/910576128-the-association-of-american-physicians-and-surgeons-files-in-the-u-s-supreme-court-in-opposition-to-mifepristone-abortion-by-mail Missouri Health Digest en PressRelease 2026-05-05T18:15:52+00:00 The Association of American Physicians and Surgeons Files in the U.S. Supreme Court in Opposition to Mifepristone Abortion-by-Mail https://ml.globenewswire.com/media/NThiZDE0ODctMDBhNC00N2UzLTkzZmMtNDUwYzc2ZTU0MjkzLTEwMzM1MTctMjAyNi0wNS0wNS1lbg==/tiny/Association-of-American-Physic.png https://www.missourihealthdigest.com/article/910565807-mesa-laboratories-inc-to-announce-fourth-quarter-and-full-fiscal-year-results-on-may-27-2026 Missouri Health Digest en PressRelease 2026-05-05T17:39:00+00:00 Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026 https://ml.globenewswire.com/media/ff66b401-9246-47b9-accc-2f553d346c5c/small/mesalogo-jpg.jpg https://www.missourihealthdigest.com/article/910565759-hantavirus-cluster-linked-to-cruise-ship-highlights-ongoing-zoonotic-risk-and-the-need-for-vigilance Missouri Health Digest en PressRelease 2026-05-05T17:20:00+00:00 Hantavirus Cluster Linked to Cruise Ship Highlights Ongoing Zoonotic Risk and the Need for Vigilance https://ml.globenewswire.com/media/6c1b2724-7b9b-469a-a7c3-bc0a64d716ae/small/gvn-lt-gr-gradiant-jpg.jpg https://www.missourihealthdigest.com/article/910565666-ergodyne-mips-bring-another-head-protection-first-to-worksites Missouri Health Digest en PressRelease 2026-05-05T17:15:00+00:00 Ergodyne + Mips Bring Another Head Protection First to Worksites https://ml.globenewswire.com/media/NGEwMDhhNTMtYmMwNC00ODBmLWJiMGItMmMzNjU3MWQ4MjdlLTExODg4MTAtMjAyNi0wNS0wNS1lbg==/tiny/Ergodyne.png https://www.missourihealthdigest.com/article/910565583-smith-nephew-drives-progress-in-chronic-wound-care-with-allevyn-complete-care-dressing-and-renasys-edge-tnpwt-set-to-launch-at-ewma-2026 Missouri Health Digest en PressRelease 2026-05-05T17:00:00+00:00 Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026 https://ml-eu.globenewswire.com/media/8512c693-36e3-49c5-9341-0e33875d614d/small/s-n-logo-jpg.jpg https://www.missourihealthdigest.com/article/910565607-scilex-holding-company-announces-its-subsidiaries-acea-therapeutics-inc-and-acea-pharma-inc-entered-into-a-definitive-agreement-with-phoenix Missouri Health Digest en PressRelease 2026-05-05T17:00:00+00:00 Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited https://ml.globenewswire.com/media/e2f985bf-0880-4d05-8838-90a69c888cf9/small/logo-jpg.jpg https://www.missourihealthdigest.com/article/910555990-american-nurses-association-calls-for-nurse-led-guardrails-on-artificial-intelligence-in-healthcare Missouri Health Digest en PressRelease 2026-05-05T16:46:15+00:00 American Nurses Association Calls for Nurse-Led Guardrails on Artificial Intelligence in Healthcare https://ml.globenewswire.com/media/ZmJhMWViYzAtNWRmOS00MDI4LThjMGEtNGFiODlhNzc2ZjZjLTUwMDE2MTk2Mi0yMDI2LTA1LTA1LWVu/tiny/American-Nurses-Enterprise.png https://www.missourihealthdigest.com/article/910545481-valneva-to-report-first-quarter-2026-consolidated-financial-results-on-may-13-2026 Missouri Health Digest en PressRelease 2026-05-05T15:45:00+00:00 Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026 https://ml-eu.globenewswire.com/media/04f398df-96ac-4b7a-8544-2a2ce2495778/small/val-logo-4c-jpg.jpg https://www.missourihealthdigest.com/article/910545482-valneva-publiera-ses-r-sultats-financiers-consolid-s-du-premier-semestre-le-13-mai-2026 Missouri Health Digest en PressRelease 2026-05-05T15:45:00+00:00 Valneva publiera ses résultats financiers consolidés du premier semestre le 13 mai 2026 https://ml-eu.globenewswire.com/media/04f398df-96ac-4b7a-8544-2a2ce2495778/small/ https://www.missourihealthdigest.com/article/910545526-allsup-named-usa-today-s-top-workplace-third-year-in-a-row Missouri Health Digest en PressRelease 2026-05-05T15:27:44+00:00 Allsup Named USA Today’s Top Workplace Third Year In A Row https://ml.globenewswire.com/media/OTVmNmRkNjctYjAzMC00Y2M3LTg2OTktODg4ZmQ5NjYxOTYxLTEwOTcwODEtMjAyNi0wNS0wNS1lbg==/tiny/Allsup.png https://www.missourihealthdigest.com/article/910545507-correction-genembryomics-and-genomic-prediction-launch-xgen-pgt-x Missouri Health Digest en PressRelease 2026-05-05T15:08:38+00:00 CORRECTION: GenEmbryomics and Genomic Prediction Launch XGEN PGT-X™ https://ml.globenewswire.com/media/ODM4NWIzMDItOGZhNy00ZTgyLWI5YTctNzE1NWI3MTk3MDU0LTEzMjMxNzktMjAyNi0wNS0wNS1lbg==/tiny/Genomic-Prediction.png https://www.missourihealthdigest.com/article/910545505-wellspan-health-opens-carlisle-hospital-expanding-emergency-care-in-a-growing-cumberland-county-corridor Missouri Health Digest en PressRelease 2026-05-05T15:07:16+00:00 WellSpan Health opens Carlisle hospital, expanding emergency care in a growing Cumberland County corridor https://ml.globenewswire.com/media/ZjI3MjljNTgtODgzMi00MGQ3LWJhMTQtZWFhNjVmMWZhZTRmLTEyMjE1MzQtMjAyNi0wNS0wNS1lbg==/tiny/WellSpan-Health.png https://www.missourihealthdigest.com/article/910536173-canadian-soccer-standout-cloey-uddenberg-and-team-physician-dr-kevin-asem-join-lung-health-foundation-s-national-push-to-keep-kids-with-asthma-in-the Missouri Health Digest en PressRelease 2026-05-05T15:00:00+00:00 Canadian Soccer Standout Cloey Uddenberg and Team Physician Dr. Kevin Asem Join Lung Health Foundation’s National Push to Keep Kids with Asthma in the Game https://ml.globenewswire.com/media/8463bfc8-e43b-49db-bf75-f2e28ae429c6/medium/play-prepared-ambassadors.jpg https://www.missourihealthdigest.com/article/910536165-atos-and-cna-strengthen-long-term-strategic-partnership-through-new-multi-year-infrastructure-services-agreement Missouri Health Digest en PressRelease 2026-05-05T14:49:42+00:00 Atos and CNA strengthen long-term strategic partnership through new multi-year infrastructure services agreement https://ml.globenewswire.com/media/3eacc37c-6163-4d11-95aa-944fca92da46/small/atos-logo-blue-rgb-png.png https://www.missourihealthdigest.com/article/910536118-the-matcha-tokyo-brings-premium-japanese-matcha-culture-to-toronto-s-ossington-strip-with-first-canadian-location-opening-may-16 Missouri Health Digest en PressRelease 2026-05-05T14:45:27+00:00 The Matcha Tokyo Brings Premium Japanese Matcha Culture to Toronto’s Ossington Strip with First Canadian Location Opening May 16 https://ml.globenewswire.com/media/Y2FiOWM5NDQtOTdkNy00ODEzLTlhN2UtZGEyZGUzMDMwZmI3LTUwMDE2MTk4NS0yMDI2LTA1LTA1LWVu/tiny/The-Matcha-Tokyo.png https://www.missourihealthdigest.com/article/910535873-global-sleep-apnea-devices-market-projected-to-exceed-usd-11-61-billion-by-2032-marketsandmarkets Missouri Health Digest en PressRelease 2026-05-05T14:45:00+00:00 Global Sleep Apnea Devices Market Projected to Exceed USD 11.61 Billion by 2032 | MarketsandMarkets™ https://ml.globenewswire.com/media/afcc5182-4ae0-43a8-a965-4351d590b7ed/small/mnm-logo-tm-jpg-jpg.JPG https://www.missourihealthdigest.com/article/910536062-your-medicare-roadmap-what-to-know-before-you-turn-65 Missouri Health Digest en PressRelease 2026-05-05T14:27:56+00:00 Your Medicare Roadmap: What to Know Before You Turn 65 https://ml.globenewswire.com/media/e29e0200-7282-4635-af4f-01abe250557e/small/feature-impact-editorlogin-logo2026-png.png https://www.missourihealthdigest.com/article/910526322-new-aua-census-shows-shifts-in-urology-workforce-practice-workloads-and-ai-use Missouri Health Digest en PressRelease 2026-05-05T14:02:00+00:00 New AUA Census Shows Shifts in Urology Workforce, Practice Workloads and AI Use https://ml.globenewswire.com/media/YWMwNjQ1Y2UtNjlmNy00MTUxLTkxMzQtYjBiNzFiNGJhNDQ5LTEyNzYxOTAtMjAyNi0wNS0wNS1lbg==/tiny/American-Urological-Associatio.png https://www.missourihealthdigest.com/article/910526620-lighthouse-autism-center-opening-new-autism-therapy-center-in-council-bluffs-iowa Missouri Health Digest en PressRelease 2026-05-05T14:00:29+00:00 Lighthouse Autism Center Opening New Autism Therapy Center in Council Bluffs, Iowa https://ml.globenewswire.com/media/e432b138-98bf-4971-921d-61bc5ac70fa7/small/lighthouse-primary-png.png https://www.missourihealthdigest.com/article/910526308-bayridge-counselling-centres-and-no-fear-counselling-corp-merge-under-ch-y-qtel-wellness-to-form-canada-s-largest-first-nation-s-owned-mental-health Missouri Health Digest en PressRelease 2026-05-05T14:00:00+00:00 Bayridge Counselling Centres and No Fear Counselling Corp Merge Under Ch’íyáqtel Wellness to Form Canada’s Largest First Nation’s Owned Mental Health Network https://ml.globenewswire.com/media/77b1c55c-807c-4a32-9598-7cafb1ac92c3/small/cw-new-logo-1-png.png https://www.missourihealthdigest.com/article/910526359-aafa-leads-group-of-patients-clinicians-asking-congress-to-protect-programs-that-help-people-with-asthma-and-allergies Missouri Health Digest en PressRelease 2026-05-05T14:00:00+00:00 AAFA Leads Group of Patients, Clinicians Asking Congress to Protect Programs that Help People with Asthma and Allergies https://ml.globenewswire.com/media/MDUxY2I5MTctZWI2Yy00NGExLThiMDEtNWM5ZjJkZDVhMWMzLTExMDE5NjItMjAyNi0wNS0wNS1lbg==/tiny/Asthma-and-Allergy-Foundation-.png https://www.missourihealthdigest.com/article/910526516-lighthouse-autism-center-opening-new-autism-therapy-center-in-mount-pleasant-iowa Missouri Health Digest en PressRelease 2026-05-05T13:48:22+00:00 Lighthouse Autism Center Opening New Autism Therapy Center in Mount Pleasant, Iowa https://ml.globenewswire.com/media/e432b138-98bf-4971-921d-61bc5ac70fa7/small/lighthouse-primary-png.png https://www.missourihealthdigest.com/article/910526307-featol-introduces-back-brace-support-belt-for-everyday-lower-back-support Missouri Health Digest en PressRelease 2026-05-05T13:32:00+00:00 FEATOL Introduces Back Brace Support Belt for Everyday Lower Back Support https://ml.globenewswire.com/media/b68de2c9-db44-424f-ba79-1b88cf5f3338/medium/featol-back-brace-rear-view-with-breathable-lightweight-mesh.png https://www.missourihealthdigest.com/article/910517765-alpha-tau-announces-upcoming-podium-presentation-at-the-ahns-12th-international-conference-on-head-and-neck-cancer-showcasing-study-results-of-alpha Missouri Health Digest en PressRelease 2026-05-05T13:14:32+00:00 Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab https://ml.globenewswire.com/media/a9de6f03-a487-4934-98e9-d25cdb4c8bed/small/atm-logo-jpg.jpg https://www.missourihealthdigest.com/article/910516832-sk-pharmteco-achieves-sbti-validation-for-2040-net-zero-science-based-targets Missouri Health Digest en PressRelease 2026-05-05T13:03:00+00:00 SK pharmteco Achieves SBTi Validation for 2040 Net-Zero Science-Based Targets https://ml.globenewswire.com/media/038236c2-8cb0-4ff3-8b7e-cbb02b768b37/small/sk-pharmteco-3-png.png https://www.missourihealthdigest.com/article/910516701-chemed-corporation-to-present-at-the-bank-of-america-securities-health-care-conference-2026 Missouri Health Digest en PressRelease 2026-05-05T13:00:00+00:00 Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2026 https://ml.globenewswire.com/media/1ab951c0-8d76-40e0-bc65-ebeaa1731e66/small/chemed-corp-logo-600x400-jpg.jpg https://www.missourihealthdigest.com/article/910516733-karl-jacob-s-fix-your-insulin-hits-1-amazon-best-seller-in-diabetes-category-launches-limited-time-0-99-reader-promotion Missouri Health Digest en PressRelease 2026-05-05T13:00:00+00:00 Karl Jacob's "Fix Your Insulin" Hits #1 Amazon Best Seller in Diabetes Category, Launches Limited-Time $0.99 Reader Promotion https://pressranger.s3.us-west-1.amazonaws.com/3242430/The-Insulin-Fix_Cover-6.jpg https://www.missourihealthdigest.com/article/910516841-heartsciences-signs-first-saas-revenues-agreement-following-full-launch-of-myovista-insights Missouri Health Digest en PressRelease 2026-05-05T13:00:00+00:00 HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™ https://ml.globenewswire.com/media/800a6aae-74f3-42bb-9199-5e169ed9b881/small/heartsciences-png.png https://www.missourihealthdigest.com/article/910517024-precision-optics-announces-receipt-of-3-5-million-follow-on-production-order-for-single-use-ophthalmic-program Missouri Health Digest en PressRelease 2026-05-05T13:00:00+00:00 Precision Optics Announces Receipt of $3.5 Million Follow-On Production Order for Single-Use Ophthalmic Program https://ml.globenewswire.com/media/6d86ce33-7e41-41e5-90b0-1c74cd89785e/small/precision-optics-logo-jpg.jpg https://www.missourihealthdigest.com/article/910517058-bicycle-health-expands-leadership-team-to-increase-access-to-evidence-based-opioid-use-disorder-care Missouri Health Digest en PressRelease 2026-05-05T13:00:00+00:00 Bicycle Health Expands Leadership Team to Increase Access to Evidence-Based Opioid Use Disorder Care https://ml.globenewswire.com/media/ba03cedc-3d11-4aa5-b226-cb5784309493/small/copy-of-bhvirtualcarelogo-black-2x-jpg.jpg https://www.missourihealthdigest.com/article/910517073-maps-state-of-colorado-partner-to-deliver-free-harm-reduction-training-for-first-responders Missouri Health Digest en PressRelease 2026-05-05T13:00:00+00:00 MAPS & State of Colorado Partner to Deliver Free Harm Reduction Training for First Responders https://ml.globenewswire.com/media/4f774750-4742-4818-be22-116e2b2085b1/small/maps-logo-2021-primary-horizontal-white-background-1200x486.jpg https://www.missourihealthdigest.com/article/910517086-femasys-enables-ob-gyns-to-deliver-first-line-fertility-treatment-with-initial-commercial-use-of-femaseed-complete Missouri Health Digest en PressRelease 2026-05-05T13:00:00+00:00 Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete https://ml.globenewswire.com/media/c668c3db-ff7f-4eb5-b51a-b8db25e838b4/small/femasys-logo-2-jpg.jpg https://www.missourihealthdigest.com/article/910517333-health-canada-authorizes-north-america-s-first-hepatitis-b-rapid-test-biolytical-s-istatis-hepatitis-b-surface-antigen-test Missouri Health Digest en PressRelease 2026-05-05T13:00:00+00:00 Health Canada Authorizes North America’s First Hepatitis B Rapid Test, bioLytical’s iStatis Hepatitis B Surface Antigen Test https://ml.globenewswire.com/media/8c4f4c4f-8565-4ee5-9842-ca4d0dcf67fb/medium/istatis-hepatitis-b-surface-antigen-test.jpg https://www.missourihealthdigest.com/article/910517373-biosphere-awarded-9-million-u-s-army-contract-to-develop-on-demand-nutrition-production-system-for-warfighters Missouri Health Digest en PressRelease 2026-05-05T13:00:00+00:00 Biosphere Awarded $9 Million U.S. Army Contract to Develop On-Demand Nutrition Production System for Warfighters https://ml.globenewswire.com/media/e816f42d-d6f4-462f-a3af-65eb8d733841/small/logo1-png.png https://www.missourihealthdigest.com/article/910516816-cellution-biologics-celebrates-expansion-of-u-s-headquarters-in-roswell-georgia Missouri Health Digest en PressRelease 2026-05-05T12:55:00+00:00 Cellution Biologics Celebrates Expansion of U.S. Headquarters in Roswell, Georgia https://ml.globenewswire.com/media/25f5b530-a1f5-4314-a4b9-9d2a0ec2a934/small/cb-logo-colorfs-png.png https://www.missourihealthdigest.com/article/910517494-clearmind-medicine-announces-filing-of-european-patent-application-for-novel-psychedelic-compounds-for-the-treatment-of-ptsd Missouri Health Digest en PressRelease 2026-05-05T12:50:00+00:00 Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD https://ml.globenewswire.com/media/bd17cbf4-8124-4f86-8a4c-1fafbb6785af/small/logo-jpg.jpg https://www.missourihealthdigest.com/article/910517538-clene-announces-7-million-underwritten-offering-of-common-stock Missouri Health Digest en PressRelease 2026-05-05T12:45:00+00:00 Clene Announces $7 Million Underwritten Offering of Common Stock https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png https://www.missourihealthdigest.com/article/910507674-ocugen-provides-business-update-with-first-quarter-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T12:32:54+00:00 Ocugen Provides Business Update with First Quarter 2026 Financial Results https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.missourihealthdigest.com/article/910506917-sab-bio-to-host-first-quarter-2026-financial-results-conference-call-and-webcast-on-may-12-2026-08-30-am-et Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET https://ml.globenewswire.com/media/6d99a771-f2c9-4d05-bf57-4f6c070df032/small/sabprimarylogocolorrgb900px72ppi-png.png https://www.missourihealthdigest.com/article/910507058-ss-innovations-surpasses-10-500-surgeries-performed-with-the-ssi-mantra-surgical-robotic-system Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 SS Innovations Surpasses 10,500 Surgeries Performed with the SSi Mantra Surgical Robotic System https://ml.globenewswire.com/media/cef267e0-040f-4889-a706-cc4d0ae49e55/small/new-logo-april-23-2025-png.png https://www.missourihealthdigest.com/article/910507118-achieve-life-sciences-to-announce-first-quarter-2026-financial-results-and-host-conference-call-and-webcast-on-may-12-2026 Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026 https://ml.globenewswire.com/media/1026e030-275c-4391-8f9a-65c5c1ec7b88/small/achieve-logo-717x800px-2-1-jpg.jpg https://www.missourihealthdigest.com/article/910507145-sofwave-medical-reports-first-quarter-fiscal-2026-financial-results-and-business-highlights Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 Sofwave Medical Reports First Quarter Fiscal 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/9fbd88c7-2eaf-45c3-b046-2d055fe94a07/small/download-png.png https://www.missourihealthdigest.com/article/910507153-disc-medicine-reports-first-quarter-2026-financial-results-and-provides-business-update Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update https://ml.globenewswire.com/media/d212c899-9a87-4500-9382-573dfe9f12af/small/disc-logo-horiz-fullcolor-rgb-jpg.jpg https://www.missourihealthdigest.com/article/910507252-palisade-bio-reports-additional-phase-1a-b-data-demonstrating-colon-targeted-exposure-and-sustained-ic90-coverage-supporting-once-daily-dosing-in Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis https://ml.globenewswire.com/media/0beaede8-1c7c-4f77-84a7-b1efd54c343c/small/logo-png.png https://www.missourihealthdigest.com/article/910507258-cormedix-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-14-2026 Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 CorMedix Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 14, 2026 https://ml.globenewswire.com/media/a14d732c-3f66-4a3c-96bb-7fc8ba5797bb/small/crmd-logo-jpg.jpg https://www.missourihealthdigest.com/article/910507278-fate-therapeutics-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 https://ml.globenewswire.com/media/2acb7cd9-5f5c-42d0-a606-72d085e2fe6e/small/fate-therapeutics-jpg.jpg https://www.missourihealthdigest.com/article/910507452-oragenics-activates-second-site-in-phase-iia-clinical-trial-of-onp-002-for-concussion-and-mild-traumatic-brain-injury Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 Oragenics Activates Second Site in Phase IIa Clinical Trial of ONP-002 for Concussion and Mild Traumatic Brain Injury. https://ml.globenewswire.com/media/8b2c9d06-f009-4a6e-a465-8a1fe9640993/small/logo-jpg.jpg https://www.missourihealthdigest.com/article/910507457-profusa-initiates-board-led-process-to-evaluate-strategic-alternatives-and-maximize-shareholder-value Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value https://ml.globenewswire.com/media/a8137a61-b858-48da-9e47-1f1bf8f6ddba/small/profusa-logo-jpg.jpg https://www.missourihealthdigest.com/article/910507458-imunon-to-hold-first-quarter-2026-financial-results-and-business-update-conference-call-on-tuesday-may-12-2026 Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026 https://ml.globenewswire.com/media/acf78e45-a45b-456b-93e3-0e39f2122826/small/logo-png.png https://www.missourihealthdigest.com/article/910507620-microbot-medical-s-liberty-endovascular-robotic-system-is-now-adopted-by-multiple-accounts-across-key-territories-including-two-access-pvi-pivotal Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites https://ml.globenewswire.com/media/346df7fb-c134-40c2-970a-39bcbaf974cd/small/mbot-logo-rgb-jpg.jpg https://www.missourihealthdigest.com/article/910507662-fibrobiologics-ceo-issues-letter-to-shareholders Missouri Health Digest en PressRelease 2026-05-05T12:30:00+00:00 FibroBiologics CEO Issues Letter to Shareholders https://ml.globenewswire.com/media/f3ebedd0-66f2-4e20-b298-4b52bbb42404/medium/pete-o-heeron.jpg https://www.missourihealthdigest.com/article/910507657-ocugen-inc-announces-pricing-of-115-million-of-6-75-convertible-senior-notes Missouri Health Digest en PressRelease 2026-05-05T12:12:21+00:00 Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes https://ml.globenewswire.com/media/18d074ba-efcd-41fd-94bc-e3bf2cc4069d/small/ocugen-4c-logo-002-png.png https://www.missourihealthdigest.com/article/910507636-blood-banking-devices-market-size-to-surpass-usd-9-08-bn-by-2034-driven-by-rising-number-of-blood-banks-globally Missouri Health Digest en PressRelease 2026-05-05T12:06:12+00:00 Blood Banking Devices Market Size to Surpass USD 9.08 BN by 2034, Driven by Rising Number of Blood Banks Globally https://ml.globenewswire.com/media/1f4cf0ab-7d76-4136-a6dc-a5545f80f538/small/zion-market-research-jpg.jpg https://www.missourihealthdigest.com/article/910507192-noom-names-power-of-habit-author-charles-duhigg-as-advisor-releases-new-research-linking-glp-1-success-to-habit-formation Missouri Health Digest en PressRelease 2026-05-05T12:02:00+00:00 Noom Names “Power of Habit” Author Charles Duhigg as Advisor, Releases New Research Linking GLP-1 Success to Habit Formation https://ml.globenewswire.com/media/6b8c0d7a-2154-4867-82d3-f7e88a9793ee/medium/noom-psychosocial-report-findings.jpg https://www.missourihealthdigest.com/article/910506877-allarity-therapeutics-advances-stenoparib-toward-pivotal-development-with-phase-3-manufacturing-campaign Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign https://ml-eu.globenewswire.com/media/fd1e4c64-f0cf-40e0-a0c9-0be0d6dce544/small/allarity-full-color-rgb-2023jun07-png.png https://www.missourihealthdigest.com/article/910506884-spyre-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update https://ml.globenewswire.com/media/bc26a912-b583-43c6-8423-55a4ba2bf4bd/small/spyre-logo-horizontal-full-color-rgb-583px-300ppi-jpg.jpg https://www.missourihealthdigest.com/article/910506912-nu-tek-biosciences-presents-data-driven-approach-to-animal-cell-culture-optimization-at-esact-2026 Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Nu-Tek BioSciences Presents Data-Driven Approach to Animal Cell Culture Optimization at ESACT 2026 https://ml.globenewswire.com/media/348e95f7-f41b-461f-94c6-c663f05170e8/small/nutek-logo-rgb-4x-jpg.jpg https://www.missourihealthdigest.com/article/910506922-nu-tek-biosciences-pr-sentiert-auf-der-esact-2026-einen-datengest-tzten-ansatz-zur-optimierung-der-tierischen-zellkultur Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Nu-Tek BioSciences präsentiert auf der ESACT 2026 einen datengestützten Ansatz zur Optimierung der tierischen Zellkultur https://ml.globenewswire.com/media/348e95f7-f41b-461f-94c6-c663f05170e8/small/nutek-logo-rgb-4x-jpg.jpg https://www.missourihealthdigest.com/article/910506928-nu-tek-biosciences-pr-sente-une-approche-fond-e-sur-les-donn-es-pour-l-optimisation-de-la-culture-de-cellules-animales-lors-de-l-esact-2026 Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Nu-Tek BioSciences présente une approche fondée sur les données pour l’optimisation de la culture de cellules animales lors de l’ESACT 2026 https://ml.globenewswire.com/media/348e95f7-f41b-461f-94c6-c663f05170e8/small/nutek-logo-rgb-4x-jpg.jpg https://www.missourihealthdigest.com/article/910506939-healthverity-to-acquire-symphony-health-uniting-clinical-data-and-commercial-analytics-to-accelerate-breakthroughs-across-the-healthcare-ecosystem Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem https://ml.globenewswire.com/media/e2010eff-0993-44c1-a40d-9f0237268a35/medium/healthverity.jpg https://www.missourihealthdigest.com/article/910506952-septerna-to-present-at-bank-of-america-securities-health-care-conference Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Septerna to Present at Bank of America Securities Health Care Conference https://ml.globenewswire.com/media/8c635733-2794-456f-9bc4-3b53908acba9/small/septernalogo-black-10x-jpg.jpg https://www.missourihealthdigest.com/article/910507011-transplants-org-launches-as-centralized-education-and-navigation-platform-for-organ-and-stem-cell-transplant-patients Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Transplants.org Launches as Centralized Education and Navigation Platform for Organ and Stem Cell Transplant Patients https://ml.globenewswire.com/media/1d980326-1679-4adb-bd02-7e4358b841ce/small/transplants-org-logo-color-jpg.jpg https://www.missourihealthdigest.com/article/910507047-clene-to-present-at-upcoming-may-conferences Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Clene to Present at Upcoming May Conferences https://ml.globenewswire.com/media/e9de96a4-582e-4975-8e43-6f3e6259c075/small/clene-logo-2x-png.png https://www.missourihealthdigest.com/article/910507089-geron-plans-to-present-at-upcoming-investor-conferences Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Geron Plans to Present at Upcoming Investor Conferences https://ml.globenewswire.com/media/e184bb51-5636-436e-8964-15613f24ca1f/small/geron-logo-jpg.jpg https://www.missourihealthdigest.com/article/910507095-minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates https://ml.globenewswire.com/media/69e604cb-25b6-4235-ae9a-17c25cc158b9/small/minerva-logo.jpg https://www.missourihealthdigest.com/article/910507163-cg-oncology-to-present-at-upcoming-investor-conferences-in-may Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 CG Oncology to Present at Upcoming Investor Conferences in May https://ml.globenewswire.com/media/9e1cbdea-928e-4ea4-b4cd-33cdc36c6b2f/small/cgoncology-cover-jpg.jpg https://www.missourihealthdigest.com/article/910507196-corbus-pharmaceuticals-to-host-in-person-and-virtual-kol-event-at-asco-2026 Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 https://ml.globenewswire.com/media/459d6fb1-b336-4d47-8aa1-f9198bda891d/small/corbus-logo-jpg.jpg https://www.missourihealthdigest.com/article/910507205-zentalis-pharmaceuticals-announces-first-patient-dosed-in-aspenova-phase-3-trial-of-azenosertib-in-patients-with-cyclin-e1-positive-platinum-resistant Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer https://ml.globenewswire.com/media/1b481d6d-51c9-44f0-b33f-81feb1061d2e/small/zentalis-logo-png.png https://www.missourihealthdigest.com/article/910507214-picard-medical-announces-pricing-of-5-million-offering Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Picard Medical Announces Pricing of $5 Million Offering https://ml.globenewswire.com/media/93c733bb-b54a-41af-856b-6d01c1f724a2/small/syncardia-x-picard-email-signature-2025-1-png.png https://www.missourihealthdigest.com/article/910507244-filana-therapeutics-presents-tsc-related-epilepsy-program-at-eilat-xviii Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII https://ml.globenewswire.com/media/984a6554-2b2a-4cf7-9a32-72ac808d52ac/small/filana400-png.png https://www.missourihealthdigest.com/article/910507247-madrigal-adds-clinical-stage-sirna-asset-targeting-pnpla3-to-its-mash-pipeline Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline https://ml.globenewswire.com/media/8fec8de1-1a2e-4f6c-a679-fc43002276ba/small/madrigal-logo-jpg.jpg https://www.missourihealthdigest.com/article/910507268-pathai-and-a-c-camargo-cancer-center-announce-cooperation-to-expand-digital-pathology-with-ai-in-brazil-via-sus Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 PathAI and A.C.Camargo Cancer Center Announce Cooperation to Expand Digital Pathology with AI in Brazil via SUS https://ml.globenewswire.com/media/ab2bfc12-ae80-47c6-9345-a98783489ed7/small/pathai-logo-standard-png.png https://www.missourihealthdigest.com/article/910507406-cogent-biosciences-reports-recent-business-highlights-and-first-quarter-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results https://ml.globenewswire.com/media/2b8cbfab-a4de-4e17-bdd6-7ef597a95d2e/small/cogent-biosciences-logo-rgb-png.png https://www.missourihealthdigest.com/article/910507408-verrica-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-a-corporate-update-on-may-12-2026 Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 https://ml.globenewswire.com/media/4938c2eb-43f1-4f6c-a1e1-82ab7fb66c3b/small/verrica-logo-jpg.jpg https://www.missourihealthdigest.com/article/910507428-bionano-announces-a-56-increase-in-publications-describing-the-utility-of-ogm-in-rare-diseases-in-q1-2026-vs-q1-2025 Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025 https://ml.globenewswire.com/media/5ba4072e-6e59-46e7-847c-6aaf7755bbbf/small/bionano-rgb-png.png https://www.missourihealthdigest.com/article/910507624-mineralys-therapeutics-to-participate-in-the-bank-of-america-securities-health-care-conference Missouri Health Digest en PressRelease 2026-05-05T12:00:00+00:00 Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference https://ml.globenewswire.com/media/2f3e6873-8e64-406e-832e-7df0f6d79a56/small/mineralys-therapeutics-logo-jpg.jpg https://www.missourihealthdigest.com/article/910507632-latest-digestive-health-supplements-market-size-expected-to-reach-usd-25-86-billion-by-2034-with-6-10-cagr-driven-by-rising-geriatric-population Missouri Health Digest en PressRelease 2026-05-05T11:59:13+00:00 [Latest] Digestive Health Supplements Market Size Expected to Reach USD 25.86 Billion by 2034 With 6.10% CAGR, Driven by Rising Geriatric Population Worldwide and Increasing Prevalence of Digestive Health Concerns https://ml.globenewswire.com/media/1f4cf0ab-7d76-4136-a6dc-a5545f80f538/small/zion-market-research-jpg.jpg https://www.missourihealthdigest.com/article/910507208-neuronetics-reports-first-quarter-2026-financial-and-operating-results Missouri Health Digest en PressRelease 2026-05-05T11:50:00+00:00 Neuronetics Reports First Quarter 2026 Financial and Operating Results https://ml.globenewswire.com/media/12db9039-d4bf-41a0-8b4a-324398e392b4/small/neuronetics-logo-rgb-purple-png.png https://www.missourihealthdigest.com/article/910497076-discure-technologies-appoints-dr-ray-baker-to-its-board-of-directors Missouri Health Digest en PressRelease 2026-05-05T11:35:00+00:00 Discure Technologies Appoints Dr. Ray Baker to its Board of Directors https://ml.globenewswire.com/media/eb02cf21-747a-4619-8cb2-b3929c46ae7e/small/descure-technologies-logo-png.PNG https://www.missourihealthdigest.com/article/910497087-kura-oncology-to-report-first-quarter-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T11:30:00+00:00 Kura Oncology to Report First Quarter 2026 Financial Results https://ml.globenewswire.com/media/ebf510d7-3727-4cc8-894f-6ce2d82b941a/small/kura-logo-for-globe-newswire-prs-png.png https://www.missourihealthdigest.com/article/910497096-intellia-therapeutics-to-participate-in-upcoming-investor-conferences Missouri Health Digest en PressRelease 2026-05-05T11:30:00+00:00 Intellia Therapeutics to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/9b6b17bb-c8a4-4009-b5f8-8cadb4d2296a/small/intellia-jpg.jpg https://www.missourihealthdigest.com/article/910497121-compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-corporate-update Missouri Health Digest en PressRelease 2026-05-05T11:30:00+00:00 Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update  https://ml.globenewswire.com/media/b8470129-5d30-4368-8074-d77404b65be8/small/compass-logo-rgb-outlines-png.png https://www.missourihealthdigest.com/article/910497160-bridgebio-to-present-primary-results-from-the-phase-3-calibrate-trial-at-2026-ece Missouri Health Digest en PressRelease 2026-05-05T11:30:00+00:00 BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE https://ml.globenewswire.com/media/2074ba9b-0e5b-41fa-baac-553f1345bb75/small/bridge-bio-black-png.png https://www.missourihealthdigest.com/article/910497222-surgery-partners-inc-announces-first-quarter-2026-results-reaffirms-full-year-2026-guidance Missouri Health Digest en PressRelease 2026-05-05T11:30:00+00:00 Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance https://ml.globenewswire.com/media/d0188456-e6d3-48f9-8479-b40422f00e4c/small/surgerypartnerslinear-1-jpg.jpg https://www.missourihealthdigest.com/article/910497278-tris-pharma-appoints-jim-potenziano-ph-d-as-chief-science-and-development-officer Missouri Health Digest en PressRelease 2026-05-05T11:30:00+00:00 Tris Pharma Appoints Jim Potenziano, Ph.D. as Chief Science and Development Officer https://ml.globenewswire.com/media/2ab6667c-5742-4090-afb8-459cd811c92e/small/logo-png.png https://www.missourihealthdigest.com/article/910497407-cytokinetics-announces-positive-topline-results-from-acacia-hcm-the-pivotal-phase-3-clinical-trial-of-aficamten-in-patients-with-non-obstructive Missouri Health Digest en PressRelease 2026-05-05T11:30:00+00:00 Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy https://ml.globenewswire.com/media/adcf634e-a2a7-4cdf-98b3-ca658eab1b35/medium/figure-1-assessments-of-kccq-and-pvo2.png https://www.missourihealthdigest.com/article/910497479-nuvectis-pharma-inc-reports-first-quarter-2026-financial-results-and-business-highlights Missouri Health Digest en PressRelease 2026-05-05T11:30:00+00:00 Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/aceda01c-bc94-4579-88fa-c0294406b49f/small/nuvectispharma-logos-final-full-color-png.png https://www.missourihealthdigest.com/article/910497039-what-to-look-for-in-a-deodorant-in-canada-in-2026 Missouri Health Digest en PressRelease 2026-05-05T11:12:15+00:00 What to Look for in a Deodorant in Canada in 2026 https://ml-eu.globenewswire.com/media/MmU2ZTI3ZDAtOWNkMi00Y2Y4LWE5N2EtZWFiZTg0NGFjZTk0LTEzMjI4ODctMjAyNi0wNS0wNS1lbg==/tiny/Beiersdorf-Canada-Inc-.png https://www.missourihealthdigest.com/article/910497392-cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of Missouri Health Digest en PressRelease 2026-05-05T11:10:00+00:00 Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.missourihealthdigest.com/article/910497403-uniqure-announces-first-quarter-2026-financial-results-and-provides-recent-company-updates Missouri Health Digest en PressRelease 2026-05-05T11:05:00+00:00 uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates https://ml.globenewswire.com/media/2ba61fe2-12e5-4a01-afe1-419652b31512/small/logo-uniqure-ms-word-orange-jpg.jpg https://www.missourihealthdigest.com/article/910497470-sotera-health-delivers-strong-first-quarter-2026-results-and-reaffirms-2026-outlook Missouri Health Digest en PressRelease 2026-05-05T11:03:49+00:00 Sotera Health Delivers Strong First-Quarter 2026 Results and Reaffirms 2026 Outlook https://ml.globenewswire.com/media/a0ec722c-ad65-4f05-a8ae-bc1aa6cc4db4/small/sotera-png.png https://www.missourihealthdigest.com/article/910497148-invivyd-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Missouri Health Digest en PressRelease 2026-05-05T11:01:00+00:00 Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/7bf12f50-1073-4ce7-81ac-89426c07add3/small/untitled-design-2-png.png https://www.missourihealthdigest.com/article/910497078-biocryst-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4 Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://ml.globenewswire.com/media/8b033909-1a3c-4811-b07b-fe03b12e00d2/small/biocryst-primarylogo-r-2c-rgb-jpg.jpg https://www.missourihealthdigest.com/article/910497083-dupixent-dupilumab-demonstrates-improved-esophageal-function-in-eosinophilic-esophagitis-eoe-phase-4-trial Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial https://ml.globenewswire.com/media/add5ebc7-88c9-49dc-8834-abbb07c622d1/small/regeneron-logo-jpg.jpg https://www.missourihealthdigest.com/article/910497093-kymera-therapeutics-presents-new-preclinical-ibd-data-for-kt-579-a-first-in-class-oral-irf5-degrader-at-digestive-disease-week Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week https://ml.globenewswire.com/media/4d3d3283-c57d-401e-9e1b-53f17e22d76b/small/kymera-logo-rgb-denim-marigold-high-res-png.png https://www.missourihealthdigest.com/article/910497116-orvida-pharma-to-present-functional-endpoint-development-data-in-rare-palmoplantar-skin-disorders-at-the-83rd-annual-meeting-of-the-society-for Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Orvida Pharma to Present Functional Endpoint Development Data in Rare Palmoplantar Skin Disorders at the 83rd Annual Meeting of the Society for Investigative Dermatology and the 2026 Epidermal Differentiation Disorders Symposium https://ml.globenewswire.com/media/cd4d7fc1-6bca-4b1d-a6b3-2314ed21fb79/small/orvida-final-46-jpg.jpg https://www.missourihealthdigest.com/article/910497194-editas-medicine-announces-first-quarter-2026-results-and-business-updates Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Editas Medicine Announces First Quarter 2026 Results and Business Updates https://ml.globenewswire.com/media/03686b66-5cbc-40b5-9dfa-be0e7858ac97/small/editas-logo-small-1-jpg.jpg https://www.missourihealthdigest.com/article/910497200-climb-bio-hosts-budoprutug-r-d-spotlight-event-highlighting-topline-subcutaneous-formulation-data-broad-b-cell-mediated-disease-opportunity-and Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts https://ml.globenewswire.com/media/2a42b557-6e44-4818-bfce-2238a05f2c43/small/climb-400x400-002-jpg.jpg https://www.missourihealthdigest.com/article/910497206-arvinas-to-report-first-quarter-2026-financial-results-on-may-12-2026 Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 https://ml.globenewswire.com/media/563780a0-f8d9-4e37-8665-b622ef2caa5b/small/arvinas-logoart-lg-jpg.jpg https://www.missourihealthdigest.com/article/910497213-sotera-health-announces-leadership-transition Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Sotera Health Announces Leadership Transition https://ml.globenewswire.com/media/a0ec722c-ad65-4f05-a8ae-bc1aa6cc4db4/small/sotera-png.png https://www.missourihealthdigest.com/article/910497215-relmada-therapeutics-to-present-ndv-01-abstracts-at-aua2026 Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026 https://ml.globenewswire.com/media/8a986b0a-11c8-4551-b0ad-ec20fe2fe40a/small/relmada-logo-png.png https://www.missourihealthdigest.com/article/910497218-fractyl-health-to-report-first-quarter-2026-financial-results-and-provide-business-updates-on-may-12-2026-and-will-participate-in-an-upcoming Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference https://ml.globenewswire.com/media/3a379315-9c07-4655-883e-7e7f26c67778/small/fractyl-logo-png.png https://www.missourihealthdigest.com/article/910497220-electra-therapeutics-announces-first-patient-dosed-in-phase-1-study-of-ipsoprubart-ela026-in-t-cell-malignancies Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Electra Therapeutics Announces First Patient Dosed in Phase 1 Study of Ipsoprubart (ELA026) in T Cell Malignancies https://ml.globenewswire.com/media/5c28c3ad-0aec-4979-b6c4-12f1d4bf4c46/small/electra-logo-rgb-png.png https://www.missourihealthdigest.com/article/910497226-brewdog-announces-partnership-with-underbelly-as-official-beer-supplier-of-underbelly-at-the-edinburgh-fringe Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 BrewDog Announces Partnership with Underbelly as Official Beer Supplier of Underbelly at the Edinburgh Fringe https://ml.globenewswire.com/media/dc1f57dc-8a83-444e-8722-08f858c451af/medium/brewdog-underbelly.jpeg https://www.missourihealthdigest.com/article/910497233-axsome-therapeutics-to-participate-in-upcoming-investor-conferences Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Axsome Therapeutics to Participate in Upcoming Investor Conferences https://ml.globenewswire.com/media/1186f248-bfb6-4258-a391-f2ffd94c5d76/small/axsome-r-morpheus-logo-pos-rgb-png.png https://www.missourihealthdigest.com/article/910497236-repligen-reports-first-quarter-2026-financial-results-and-updates-full-year-2026-financial-guidance Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance https://ml.globenewswire.com/media/967d43f6-7ffd-4ee0-8804-e3c12952402f/small/repligen-logo-horizontal-withtagline-1-jpg.jpg https://www.missourihealthdigest.com/article/910497247-atea-pharmaceuticals-to-host-first-quarter-2026-financial-results-and-business-update-conference-call-on-may-12-2026 Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026 https://ml.globenewswire.com/media/1506ab30-7618-4ed0-98de-e3815adb3aa6/small/avir-png.png https://www.missourihealthdigest.com/article/910497290-seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates https://ml.globenewswire.com/media/f8c3ad50-d1a3-457d-b0c7-8f9237db7f93/small/seres-logo-png.png https://www.missourihealthdigest.com/article/910497311-eupraxia-pharmaceuticals-reports-erefs-data-from-its-ongoing-phase-1b-2a-resolve-trial-in-eosinophilic-esophagitis-at-digestive-disease-week-ddw Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) https://ml.globenewswire.com/media/0b2bbe4b-1cf9-402e-8ea6-22c0043f310a/small/eupraxia-color-med-res-01-jpg.jpg https://www.missourihealthdigest.com/article/910497313-ocular-therapeutix-reports-first-quarter-2026-financial-results-and-business-highlights Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights https://ml.globenewswire.com/media/20ee0f50-7288-4f81-8546-f2ad2050ddbf/small/ocul-logo-jpg.jpg https://www.missourihealthdigest.com/article/910497336-rhythm-pharmaceuticals-reports-first-quarter-2026-financial-results-and-business-update Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update https://ml.globenewswire.com/media/b767aaa5-9915-465f-9233-d97757f4e387/small/rhythm-logo-rgb-jpg-registration-mark-jpg.jpg https://www.missourihealthdigest.com/article/910497362-nrx-pharmaceuticals-nasdaq-nrxp-announces-initiation-of-commercial-manufacturing-for-preservative-free-ketamine Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine https://ml.globenewswire.com/media/d879f1ff-d5d7-48d7-9731-c881b469d873/small/nrx-logo-300dpi-png.png https://www.missourihealthdigest.com/article/910497386-neuraxis-to-host-first-quarter-2026-results-and-business-update-call-on-tuesday-may-12-2026 Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 NeurAxis to Host First Quarter 2026 Results and Business Update Call on Tuesday, May 12, 2026 https://ml.globenewswire.com/media/a1e3887d-3378-46c5-938d-2b0d5a7c825f/small/neuraxis-logo-png.png https://www.missourihealthdigest.com/article/910497398-shopify-delivers-again-as-merchants-clear-100-billion-in-q1-gmv Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Shopify Delivers Again as Merchants Clear $100 Billion in Q1 GMV https://ml.globenewswire.com/media/28cdf29b-fa48-43e3-a710-ea3ab811a26c/small/shopify-logo-black-png.png https://www.missourihealthdigest.com/article/910497412-cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million Missouri Health Digest en PressRelease 2026-05-05T11:00:00+00:00 Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million https://ml.globenewswire.com/media/980abc5d-826f-4ac3-ad81-f07d69b34af6/small/cellectar-logo-1-jpg.jpg https://www.missourihealthdigest.com/article/910487809-biontech-ver-ffentlicht-ergebnisse-f-r-das-erste-quartal-2026-sowie-informationen-zur-gesch-ftsentwicklung Missouri Health Digest en PressRelease 2026-05-05T10:45:00+00:00 BioNTech veröffentlicht Ergebnisse für das erste Quartal 2026 sowie Informationen zur Geschäftsentwicklung https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/ https://www.missourihealthdigest.com/article/910487854-biontech-announces-first-quarter-2026-financial-results-and-corporate-update Missouri Health Digest en PressRelease 2026-05-05T10:45:00+00:00 BioNTech Announces First Quarter 2026 Financial Results and Corporate Update https://ml-eu.globenewswire.com/media/b9e2e00e-f790-4d54-a01f-4c85716b01bd/small/190705-biontech-logo-rgb-dark-green-preferred-0-png.png https://www.missourihealthdigest.com/article/910488042-diagonal-therapeutics-expands-executive-leadership-team-appoints-industry-veteran-jonathan-piazza-as-chief-financial-officer Missouri Health Digest en PressRelease 2026-05-05T10:30:00+00:00 Diagonal Therapeutics Expands Executive Leadership Team, Appoints Industry Veteran Jonathan Piazza as Chief Financial Officer https://ml.globenewswire.com/media/c2298dfb-0954-43a2-ae2e-866e7a08c7ad/small/diagonallogo-darkcolor-png.png https://www.missourihealthdigest.com/article/910487933-new-cda-data-reveals-disconnect-between-knowing-the-risks-of-tanning-and-behaviour-among-gen-z Missouri Health Digest en PressRelease 2026-05-05T10:00:00+00:00 New CDA Data Reveals Disconnect Between Knowing the Risks of Tanning and Behaviour Among Gen Z https://ml.globenewswire.com/media/b78c656b-c304-4227-95af-3944fa238da2/medium/sun-awareness-month-2026.png https://www.missourihealthdigest.com/article/910487988-de-nouvelles-donn-es-de-l-acd-r-v-lent-un-d-calage-entre-la-conscience-de-la-g-n-ration-z-des-risques-li-s-au-bronzage-et-ses-habitudes-de-protection Missouri Health Digest en PressRelease 2026-05-05T10:00:00+00:00 De nouvelles données de l’ACD révèlent un décalage entre la conscience de la génération Z des risques liés au bronzage et ses habitudes de protection solaire https://ml.globenewswire.com/media/b78c656b-c304-4227-95af-3944fa238da2/medium/mois-de-mai-le-mois-de-la-prudence-au-soleil-2026.png https://www.missourihealthdigest.com/article/910488059-paws-itively-paw-litical-voting-opens-for-4th-annual-cutest-pets-on-parliament-hill Missouri Health Digest en PressRelease 2026-05-05T10:00:00+00:00 Paws-itively Paw-litical: Voting Opens for 4th Annual Cutest Pets on Parliament Hill https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.missourihealthdigest.com/article/910488062-poil-itiquement-patte-tant-le-vote-est-ouvert-pour-le-quatri-me-concours-annuel-les-animaux-de-compagnie-les-plus-mignons-sur-la-colline-du Missouri Health Digest en PressRelease 2026-05-05T10:00:00+00:00 Poil-itiquement é-patte-tant : Le vote est ouvert pour le quatrième concours annuel « Les animaux de compagnie les plus mignons sur la Colline du Parlement » https://ml.globenewswire.com/media/197c2953-84e0-435d-8524-c68da19d27e9/small/cahi-logo-jpg.JPG https://www.missourihealthdigest.com/article/910488114-integra-lifesciences-announces-leadership-transition Missouri Health Digest en PressRelease 2026-05-05T10:00:00+00:00 Integra LifeSciences Announces Leadership Transition https://ml.globenewswire.com/media/5adce648-cb01-457f-83ba-c7a1895d1515/medium/stuart-essig-chairman-and-chief-executive-officer.png https://www.missourihealthdigest.com/article/910488123-fortrea-reports-first-quarter-2026-results Missouri Health Digest en PressRelease 2026-05-05T10:00:00+00:00 Fortrea Reports First Quarter 2026 Results https://ml.globenewswire.com/media/9fbbe00b-8782-464e-83e6-5843c563884a/small/fortrea-logo-jpg.jpg https://www.missourihealthdigest.com/article/910488127-aclarion-announces-second-commercial-agreement-with-weill-cornell-medicine Missouri Health Digest en PressRelease 2026-05-05T10:00:00+00:00 Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine https://ml.globenewswire.com/media/6650177f-80b7-4c94-afb4-fc63aa3ada98/small/logo-png.png https://www.missourihealthdigest.com/article/910488131-integra-lifesciences-reports-first-quarter-2026-financial-results Missouri Health Digest en PressRelease 2026-05-05T10:00:00+00:00 Integra LifeSciences Reports First Quarter 2026 Financial Results https://ml.globenewswire.com/media/80d27f1a-2d8e-44f2-92e9-57e14db38652/small/integra-promotional-logos-integra-logo-full-color-process-1.png https://www.missourihealthdigest.com/article/910488144-anteris-technologies-announces-first-u-s-patients-treated-in-global-pivotal-paradigm-trial Missouri Health Digest en PressRelease 2026-05-05T10:00:00+00:00 Anteris Technologies Announces First U.S. Patients Treated in Global Pivotal PARADIGM Trial https://ml.globenewswire.com/media/90a5ae8d-7cf0-4a3d-b38c-f4ad7e3fbf0e/small/anteris-tech-rgb-blue-png.png https://www.missourihealthdigest.com/article/910458835-latest-findings-from-dme-aware-delphi-study-presented-at-arvo-2026-annual-meeting Missouri Health Digest en PressRelease 2026-05-05T08:00:00+00:00 Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting https://ml-eu.globenewswire.com/media/dc25de9c-07c8-448a-b6af-aea02249e593/medium/global-consensus-on-early-intervention-in-dme.png https://www.missourihealthdigest.com/article/910448820-4bio-capital-leads-oversubscribed-61-million-83m-series-a-financing-of-cytospire-therapeutics Missouri Health Digest en PressRelease 2026-05-05T07:05:00+00:00 4BIO Capital leads oversubscribed £61 million ($83m) Series A financing of Cytospire Therapeutics  https://ml-eu.globenewswire.com/media/fab6412c-5edc-4903-8a71-51e5ccc6accb/small/4bio-capital-logo-png.png https://www.missourihealthdigest.com/article/910448817-cytospire-therapeutics-announces-oversubscribed-61-million-83m-series-a-financing-to-advance-pipeline-of-first-in-class-pan-gamma-delta-t-cell Missouri Health Digest en PressRelease 2026-05-05T07:00:00+00:00 Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer https://ml-eu.globenewswire.com/media/99e8d7e3-84e7-41a5-84aa-4f03dcb8e2be/medium/natalie-mount.jpg https://www.missourihealthdigest.com/article/910448827-neurocare-ag-mdma-tms Missouri Health Digest en PressRelease 2026-05-05T07:00:00+00:00 تعلن مجموعة neurocare AG عن ترخيص تسويق الأجهزة الطبية (MDMA) لبيع أجهزة التحفيز المغناطيسي عبر الجمجمة (TMS) في المملكة العربية السعودية https://ml-eu.globenewswire.com/media/d4455b17-37a7-4b42-8dc5-719bbbfe483b/medium/patient-receives-tms-therapy-for-depression-with-neurocare-s.jpg https://www.missourihealthdigest.com/article/910448841-neurocare-group-ag-announces-mdma-approval-of-tms-devices-in-saudi-arabia Missouri Health Digest en PressRelease 2026-05-05T07:00:00+00:00 neurocare group AG announces MDMA approval of TMS Devices in Saudi Arabia https://ml-eu.globenewswire.com/media/d4455b17-37a7-4b42-8dc5-719bbbfe483b/medium/patient-receives-depression-treatment-using-neurocares-apoll.jpg https://www.missourihealthdigest.com/article/910448845-novonesis-delivered-strong-start-to-the-year-with-7-organic-sales-growth-in-q1 Missouri Health Digest en PressRelease 2026-05-05T06:18:16+00:00 Novonesis delivered strong start to the year with 7% organic sales growth in Q1 https://ml-eu.globenewswire.com/media/d0c3bcb0-65ab-400f-9219-15fbf4253148/small/novonesis-logo-1-png.png https://www.missourihealthdigest.com/article/910439198-abivax-announces-repurchase-of-royalty-certificates-and-pricing-of-45m-38-5m-offering-of-american-depositary-shares Missouri Health Digest en PressRelease 2026-05-05T06:00:00+00:00 Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares https://ml-eu.globenewswire.com/media/5470cd7e-c1fe-402f-8673-925c82bbd2fb/small/abivax-logo-rgb-png.png https://www.missourihealthdigest.com/article/910429701-santhera-ver-ffentlicht-einladung-zur-ordentlichen-generalversammlung Missouri Health Digest en PressRelease 2026-05-05T05:00:00+00:00 Santhera veröffentlicht Einladung zur ordentlichen Generalversammlung https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/ https://www.missourihealthdigest.com/article/910429709-santhera-publishes-agenda-for-its-annual-general-meeting Missouri Health Digest en PressRelease 2026-05-05T05:00:00+00:00 Santhera Publishes Agenda for its Annual General Meeting https://ml-eu.globenewswire.com/media/63cd960e-70ce-4ba8-8984-92f72954c235/small/logo-jpg.JPG https://www.missourihealthdigest.com/article/910410639-axavive-under-investigation-inspecting-the-axon-renewal-anti-aging-benefits-of-the-secret-golden-seed-astragaloside-iv-skin-care-supplement Missouri Health Digest en PressRelease 2026-05-05T02:59:01+00:00 Axavive Under Investigation: Inspecting the Axon Renewal Anti-Aging Benefits of the Secret Golden Seed Astragaloside IV Skin Care Supplement https://zingfast.com/wp-content/uploads/2026/05/Axavive-Axon-Renewal.jpg https://www.missourihealthdigest.com/article/910262406-tinysuperheroes-launches-may-discovery-mission-with-support-from-sfc-group-to-spark-curiosity-and-social-awareness Missouri Health Digest en PressRelease 2026-05-04T14:38:10+00:00 TinySuperheroes Launches May Discovery Mission with Support from SFC Group to Spark Curiosity and Social Awareness https://d2c0db5b8fb27c1c9887-9b32efc83a6b298bb22e7a1df0837426.ssl.cf2.rackcdn.com/24846925-tsh-2000x1429.png https://www.missourihealthdigest.com/article/910400806-gl-control-claims-evaluated-investigating-the-ingredients-benefits-for-blood-sugar-trap-support Missouri Health Digest en PressRelease 2026-05-05T02:26:09+00:00 GL Control Claims Evaluated: Investigating the Ingredients Benefits for Blood Sugar Trap Support https://zingfast.com/wp-content/uploads/2026/05/GL-Control-1.jpg https://www.missourihealthdigest.com/article/910400749-vital-wrist-monitor-vital-wrist-ball-under-investigation-evaluating-the-brand-claims-product-benefits Missouri Health Digest en PressRelease 2026-05-05T01:55:19+00:00 Vital Wrist Monitor & Vital Wrist Ball Under Investigation: Evaluating the Brand Claims & Product Benefits https://zingfast.com/wp-content/uploads/2026/05/Vital-Wrist-Monitor-Vital-Wrist-Ball.jpg https://www.missourihealthdigest.com/article/910391392-apa-welcomes-national-focus-on-mental-health-urges-evidence-based-approach-and-continued-focus-on-access-to-care Missouri Health Digest en PressRelease 2026-05-05T01:41:48+00:00 APA Welcomes National Focus on Mental Health, Urges Evidence-Based Approach and Continued Focus on Access to Care https://ml.globenewswire.com/media/ODc3ZjcyMWMtNDEyOC00Njc4LWE1MzQtNjQ0YzkzNjhiZDI4LTEyNjc0MTAtMjAyNi0wNS0wNS1lbg==/tiny/American-Psychiatric-Associati.png https://www.missourihealthdigest.com/article/910391357-axavive-claims-evaluated-the-golden-seed-switch-for-healthy-skin-support Missouri Health Digest en PressRelease 2026-05-05T01:28:26+00:00 Axavive Claims Evaluated: The Golden Seed Switch for Healthy Skin Support https://zingfast.com/wp-content/uploads/2026/05/Axavive.jpg https://www.missourihealthdigest.com/article/910371205-pennant-announces-first-quarter-2026-earnings-release-and-call Missouri Health Digest en PressRelease 2026-05-04T23:34:37+00:00 Pennant Announces First Quarter 2026 Earnings Release and Call https://ml.globenewswire.com/media/d50f543c-fc54-437d-8007-600644587dfe/small/pennant-logo-png.png https://www.missourihealthdigest.com/article/910361255-janell-rae-releases-debut-book-satori-awakening-to-your-truest-self-through-energy-intelligence Missouri Health Digest en PressRelease 2026-05-04T22:40:00+00:00 Janell Rae Releases Debut Book Satori: Awakening to Your Truest Self Through Energy Intelligence https://pressranger.s3.us-west-1.amazonaws.com/3225770/Janell-Book-Cover-%288%29.png https://www.missourihealthdigest.com/article/910351918-ballad-health-invests-15-million-to-expand-robotic-assisted-surgery-earns-national-accreditation-for-quality-and-surgical-excellence Missouri Health Digest en PressRelease 2026-05-04T22:28:36+00:00 Ballad Health invests $15 million to expand robotic-assisted surgery, earns national accreditation for quality and surgical excellence https://ml.globenewswire.com/media/ODk2ZWQ5ZTQtY2ZhZC00YzBmLTkyNDQtNTg2Y2VhYzgxZTkyLTExMzUxNTItMjAyNi0wNS0wNC1lbg==/tiny/Ballad-Health.png https://www.missourihealthdigest.com/article/910351879-elite-pro-force-male-enhancement-gummies-claims-evaluated-the-ultra-peak-horse-gelatin-trick-for-men Missouri Health Digest en PressRelease 2026-05-04T21:49:17+00:00 Elite Pro Force Male Enhancement Gummies Claims Evaluated: The Ultra Peak Horse Gelatin Trick for Men https://zingfast.com/wp-content/uploads/2026/05/Elite-Pro-Force-Male-Enhancement-Gummies.jpg https://www.missourihealthdigest.com/article/910342560-nanobiotix-announces-protocol-amendment-to-ongoing-global-phase-3-head-and-neck-cancer-study Missouri Health Digest en PressRelease 2026-05-04T21:29:27+00:00 Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.missourihealthdigest.com/article/910342587-nanobiotix-annonce-un-amendement-du-protocole-de-l-tude-mondiale-de-phase-3-sur-le-cancer-de-la-t-te-et-du-cou Missouri Health Digest en PressRelease 2026-05-04T21:29:27+00:00 NANOBIOTIX ANNONCE UN AMENDEMENT DU PROTOCOLE DE L’ÉTUDE MONDIALE DE PHASE 3 SUR LE CANCER DE LA TÊTE ET DU COU https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg